Pharmaceutical News

RSS

Leishmania parasite develops combined resistance against drug, human immune system

Scientists of the Institute of Tropical Medicine (ITG) discovered a parasite that not only had developed resistance against a common medicine, but at the same time had become better in withstanding the human immune system.

22 Dec 2011

Malaria vaccine shows early success

An experimental vaccine for malaria has been developed by British scientists. It has shown early potential to neutralize many, perhaps all, strains of the deadliest malaria parasite.

21 Dec 2011

CutisPharma introduces FIRST - Mouthwash Kits

CutisPharma, Inc. announced the introduction of FIRST - Mouthwash BLM 4oz and FIRST - Mouthwash BLM 6oz compounding kits. These products expand the FIRST Magic Mouthwash line for CutisPharma.

21 Dec 2011

Actavis enters LOI with QRxPharma to commercialize MoxDuo IR in the U.S.

Actavis Group, the international generic pharmaceuticals company, today announced that its US subsidiary, Actavis Inc, has entered into a binding letter of intent (LOI) with QRxPharma Limited to commercialize MoxDuo IR in the United States.

21 Dec 2011

Optical imaging can visualize cultured cancer cells' response to particular drug

Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon as possible how a cancer is affected by treatment, researchers from Vanderbilt University are striving to design tests that assess treatment response rapidly, accurately, and cost-effectively.

21 Dec 2011

Low-income neighborhoods often misinformed about emergency contraception access

Researchers from Boston Medical Center (BMC) and Boston University School of Medicine (BUSM) have found that in low-income neighborhoods, misinformation about access to emergency contraception is a common occurrence.

21 Dec 2011

Ranbaxy signs consent decree with U.S. FDA

Ranbaxy Laboratories Ltd. today announced that it has signed a consent decree with the U.S. Food and Drug Administration.

21 Dec 2011

FDA accepts Pfizer's tofacitinib NDA for review

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tofacitinib (development code CP-690,550), an investigational novel, oral JAK inhibitor being studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

21 Dec 2011

University of Oxford scientists develop new candidate malaria vaccine

A new candidate malaria vaccine with the potential to neutralise all strains of the most deadly species of malaria parasite has been developed by a team led by scientists at the University of Oxford.

21 Dec 2011

Takeda receives FDA approval for EDARBYCLOR to treat hypertension

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Food and Drug Administration (FDA) approved EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the treatment of hypertension to lower blood pressure in adults.

21 Dec 2011

Amgen and Watson to collaborate on biosimilar anti-cancer drugs

Amgen, the largest standalone biotechnology company, and generic drug firm Watson Pharmaceuticals will collaborate on developing biosimilar drugs for cancer.

20 Dec 2011

Drug prices may fall by up to 82 percent in Australia

There is good news for patients who regularly take drugs for conditions such as high blood pressure and diabetes. The prices of these medicines in Australia could be reduced sharply from next year.

20 Dec 2011

WHO approves three Mylan ARV therapies to treat HIV/AIDS

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received approval for three antiretroviral (ARV) therapies used to treat HIV/AIDS under the World Health Organization's (WHO) Prequalification of Medicines Programme. The products include:

20 Dec 2011

MacroGenics to receive milestone payment from Boehringer Ingelheim

MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced today that it will receive a milestone payment from Boehringer Ingelheim.

20 Dec 2011

Immunosuppressant combination improves survival of human spinal stem cells in ALS rat model

A team of researchers grafting human spinal stem cells into rats modeled with amyotrophic lateral sclerosis (ALS), also known as "Lou Gehrig's Disease," a degenerative, lethal, neuromuscular disease, have tested four different immunosuppressive protocols aimed at determining which regimen improved long-term therapeutic effects.

20 Dec 2011

SCYNEXIS, MMV assemble Malaria Box of 400 compounds with antimalarial activity

In a bid to catalyse malaria and neglected disease drug discovery, MMV and SCYNEXIS, Inc. have assembled a Malaria Box of 400 carefully selected commercially available compounds with antimalarial activity and will provide it to researchers at no cost.

20 Dec 2011

Pfizer, GlaxoSmithKline to increase sales of pneumococcal vaccines through GAVI

Pharmaceutical companies Pfizer and GlaxoSmithKline are increasing their sales of reduced-cost pneumonia vaccines to developing countries through the GAVI Alliance "by more than 50 percent, marking the scale-up of an international program to protect millions of children," Reuters reports.

20 Dec 2011

Three-dose artesunate therapy effective in treating children with malaria

A shorter anti-malaria treatment is as effective in treating seriously ill children as the standard regimen, according to new research. Researchers have shown that three doses over two days of the drug artesunate are as effective in killing the malaria parasite in the blood as five doses over three days.

20 Dec 2011

Eculizumab protects children from severe Shiga toxin-associated HUS

A physician and researcher at the Sainte Justine University Hospital Center (Sainte-Justine UHC), a University of Montreal affiliate, saved the life of a child and, by doing so, became the first to find a new use for a drug in the fight against deadly E. coli bacteria.

20 Dec 2011

Lostartan can reduce cigarette smoke-induced lung injury

Chronic obstructive pulmonary disease (COPD) is among the most common causes of death in the US. It is a smoking-related disease for which there are currently no disease-altering therapies. However, hope that one could be developed is now provided by the work of Enid Neptune and colleagues, at Johns Hopkins University, Baltimore, in a mouse model of lung disease caused by exposure to cigarette smoke.

20 Dec 2011